Esperion Therapeutics Inc.
NEWS
Products getting regulatory approval and hitting the market doesn’t always spell success for companies, especially during a global pandemic. Michigan-based Esperion has learned that lesson all too well.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The collaboration for development and commercialization combines Esperion’s knowledge in lipid management and Otsuka’s extensive cardiovascular drug advancement and marketing in Japan.
Nexlizet is expected to be on the market in the U.S. in July 2020.
The company is planning for its drug for cholesterol lowering medications to hit the streets by the end of March. It will provide a new option to all the patients.
The U.S. Food and Drug Administration has a busy week planned for drug review. Here’s a look at this week’s schedule.
Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
Esperion provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.
Esperion announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
JOBS
IN THE PRESS